Aralez Pharmaceuticals Inc (NASDAQ:ARLZ) – Investment analysts at Zacks Investment Research issued their Q1 2017 earnings per share (EPS) estimates for shares of Aralez Pharmaceuticals in a note issued to investors on Thursday. Zacks Investment Research analyst D. Bautz expects that the firm will post earnings of ($0.48) per share for the quarter. Zacks Investment Research also issued estimates for Aralez Pharmaceuticals’ Q2 2017 earnings at ($0.47) EPS, Q3 2017 earnings at ($0.42) EPS, Q4 2017 earnings at ($0.36) EPS, FY2017 earnings at ($1.73) EPS and FY2018 earnings at ($1.64) EPS.

Separately, Chardan Capital cut their target price on shares of Aralez Pharmaceuticals from $10.00 to $5.50 and set a “buy” rating on the stock in a report on Wednesday, March 15th.

Your IP Address:

Aralez Pharmaceuticals (NASDAQ:ARLZ) opened at 2.36 on Monday. Aralez Pharmaceuticals has a 12-month low of $2.05 and a 12-month high of $6.80. The firm’s 50-day moving average is $3.88 and its 200 day moving average is $4.58. The firm’s market cap is $154.58 million.

Aralez Pharmaceuticals (NASDAQ:ARLZ) last released its quarterly earnings data on Monday, March 13th. The company reported ($0.37) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.26) by $0.11. Aralez Pharmaceuticals had a negative return on equity of 65.67% and a negative net margin of 211.76%. The business had revenue of $20 million for the quarter, compared to analyst estimates of $21.86 million. During the same quarter in the previous year, the company posted ($0.40) EPS. The business’s quarterly revenue was up 233.3% on a year-over-year basis.

A number of hedge funds have recently added to or reduced their stakes in the stock. Shufro Rose & Co. LLC boosted its stake in Aralez Pharmaceuticals by 30.3% in the third quarter. Shufro Rose & Co. LLC now owns 21,487 shares of the company’s stock valued at $104,000 after buying an additional 5,000 shares during the period. FNY Managed Accounts LLC boosted its stake in Aralez Pharmaceuticals by 13.5% in the third quarter. FNY Managed Accounts LLC now owns 59,000 shares of the company’s stock valued at $286,000 after buying an additional 7,000 shares during the period. Dimensional Fund Advisors LP boosted its stake in Aralez Pharmaceuticals by 2.3% in the fourth quarter. Dimensional Fund Advisors LP now owns 314,224 shares of the company’s stock valued at $1,386,000 after buying an additional 7,014 shares during the period. Integre Asset Management LLC boosted its stake in Aralez Pharmaceuticals by 31.7% in the fourth quarter. Integre Asset Management LLC now owns 81,938 shares of the company’s stock valued at $361,000 after buying an additional 19,715 shares during the period. Finally, Wells Fargo & Company MN boosted its stake in Aralez Pharmaceuticals by 9.4% in the third quarter. Wells Fargo & Company MN now owns 260,769 shares of the company’s stock valued at $1,265,000 after buying an additional 22,441 shares during the period. Institutional investors and hedge funds own 44.01% of the company’s stock.

In related news, CEO Adrian Adams purchased 500,000 shares of the business’s stock in a transaction that occurred on Wednesday, March 15th. The shares were acquired at an average price of $2.46 per share, for a total transaction of $1,230,000.00. Following the completion of the acquisition, the chief executive officer now directly owns 3,569,230 shares in the company, valued at approximately $8,780,305.80. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Arthur S. Kirsch purchased 45,000 shares of the business’s stock in a transaction that occurred on Wednesday, March 15th. The stock was bought at an average price of $2.27 per share, for a total transaction of $102,150.00. Following the acquisition, the director now owns 149,109 shares of the company’s stock, valued at $338,477.43. The disclosure for this purchase can be found here. Insiders bought 549,750 shares of company stock worth $1,342,173 in the last 90 days. Company insiders own 6.77% of the company’s stock.

Aralez Pharmaceuticals Company Profile

Aralez Pharmaceuticals Inc is a Canada-based specialty pharmaceutical company. The Company focuses on acquiring, developing and commercializing products in cardiovascular, pain and other areas. The Company’s products include Fibricor, Cambia, Fiorinal, Fiorinal C, Soriatane, Bezalip SR, NeoVisc, Uracyst, Durela, Proferrin, Resultz and Collatamp G.

5 Day Chart for NASDAQ:ARLZ

Receive News & Ratings for Aralez Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aralez Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.